MediciNova, Inc. (MNOV)

NASDAQ: MNOV · IEX Real-Time Price · USD
+0.07 (3.93%)
At close: Nov 28, 2023, 4:00 PM
-0.06 (-3.24%)
After-hours: Nov 28, 2023, 4:54 PM EST

Company Description

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States.

It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction.

The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers.

It has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

MediciNova, Inc.
MediciNova logo
Country United States
Founded 2000
IPO Date Feb 8, 2005
Industry Biotechnology
Sector Healthcare
Employees 13
CEO Dr. Yuichi Iwaki M.D., Ph.D.

Contact Details

4275 Executive Square, Suite 300
La Jolla, California 92037
United States
Phone 858-373-1500

Stock Details

Ticker Symbol MNOV
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001226616
CUSIP Number 58468P206
ISIN Number US58468P2065
Employer ID 33-0927979
SIC Code 2834

Key Executives

Name Position
Dr. Yuichi Iwaki M.D., Ph.D. Co-Founder, President, Chief Executive Officer and Executive Director
Dr. Kazuko Matsuda M.D., M.P.H., MPH, Ph.D. Chief Medical Officer and Director
Jason J. Kruger CPA Chief Financial Officer and Principal Financial Officer
Dr. David H. Crean M.B.A., Ph.D. Chief Business Officer
John O'Neil CPA Controller

Latest SEC Filings

Date Type Title
Nov 9, 2023 10-Q Quarterly Report
Aug 9, 2023 10-Q Quarterly Report
Aug 7, 2023 8-K Current Report
Jun 22, 2023 8-K Current Report
Jun 14, 2023 8-K Current Report
May 11, 2023 10-Q Quarterly Report
Apr 26, 2023 8-K Current Report
Apr 26, 2023 ARS Filing
Apr 26, 2023 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 26, 2023 DEF 14A Other definitive proxy statements